Παρασκευή 31 Μαρτίου 2017

The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer

alertIcon.gif

Publication date: Available online 30 March 2017
Source:Hematology/Oncology Clinics of North America
Author(s): Adrian G. Murphy, Ronan J. Kelly

Teaser

The connection between inflammation and malignancy has long been recognized in gastric and esophageal cancers. Given the considerable success of immune checkpoint inhibitors in other tumor types, for example, lung cancer and melanoma, much attention is being paid to furthering their role in gastric and esophageal cancers. The Cancer Genome Atlas has provided further details of the molecular heterogeneity of these tumors, which may help predict responsiveness to immune checkpoint inhibitors. This article discusses the rationale for investigating these agents in gastroesophageal cancer and summarizes the relevant clinical trial data and ongoing studies.


http://ift.tt/2mWOQ3D

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου